180 related articles for article (PubMed ID: 36122452)
1. De Novo design of a humanized antiCD33 antibody-oridonin conjugate for acute myeloid leukemia therapy.
Feng H; Liu Y; Zhang M; Liu R; Wang J; Wang W; He P; Zhang P; Niu F
Biochem Biophys Res Commun; 2022 Nov; 629():152-158. PubMed ID: 36122452
[TBL] [Abstract][Full Text] [Related]
2. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
[TBL] [Abstract][Full Text] [Related]
3. LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.
Anami Y; Deng M; Gui X; Yamaguchi A; Yamazaki CM; Zhang N; Zhang CC; An Z; Tsuchikama K
Mol Cancer Ther; 2020 Nov; 19(11):2330-2339. PubMed ID: 32879051
[TBL] [Abstract][Full Text] [Related]
4. [Gemtuzumab ozogamicin and targeted cancer therapy].
Imaizumi M
Nihon Yakurigaku Zasshi; 2004 Jul; 124(1):25-9. PubMed ID: 15226619
[TBL] [Abstract][Full Text] [Related]
5. Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?
O'Hear C; Rubnitz JE
Expert Rev Hematol; 2014 Aug; 7(4):427-9. PubMed ID: 24871925
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
[TBL] [Abstract][Full Text] [Related]
7. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.
Cianfriglia M
Ann Ist Super Sanita; 2013; 49(2):150-68. PubMed ID: 23771260
[TBL] [Abstract][Full Text] [Related]
8. Gemtuzumab ozogamicin in acute myeloid leukemia.
Godwin CD; Gale RP; Walter RB
Leukemia; 2017 Sep; 31(9):1855-1868. PubMed ID: 28607471
[TBL] [Abstract][Full Text] [Related]
9. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults.
Goldenson BH; Goodman AM; Ball ED
Expert Opin Biol Ther; 2021 Jul; 21(7):849-862. PubMed ID: 32990476
[TBL] [Abstract][Full Text] [Related]
10. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
Walter RB; Boyle KM; Appelbaum FR; Bernstein ID; Pagel JM
Blood; 2008 May; 111(9):4813-6. PubMed ID: 18326813
[TBL] [Abstract][Full Text] [Related]
11. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
12. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
Linenberger ML
Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
[TBL] [Abstract][Full Text] [Related]
13. What happened to anti-CD33 therapy for acute myeloid leukemia?
Jurcic JG
Curr Hematol Malig Rep; 2012 Mar; 7(1):65-73. PubMed ID: 22109628
[TBL] [Abstract][Full Text] [Related]
14. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
15. [Gemtuzumab ozogamicin for treatment of acute myeloid leukemia].
Brotelle T; Lemal R; Moluçon-Chabrot C; Bay JO; Delaunay J; Guièze R
Bull Cancer; 2014 Feb; 101(2):211-8. PubMed ID: 24557850
[TBL] [Abstract][Full Text] [Related]
16. Gemtuzumab ozogamicin for acute myeloid leukemia.
Appelbaum FR; Bernstein ID
Blood; 2017 Nov; 130(22):2373-2376. PubMed ID: 29021230
[TBL] [Abstract][Full Text] [Related]
17. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
[TBL] [Abstract][Full Text] [Related]
18. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.
Baron J; Wang ES
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):549-559. PubMed ID: 29787320
[TBL] [Abstract][Full Text] [Related]
19. In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.
Petrich T; Korkmaz Z; Krull D; Frömke C; Meyer GJ; Knapp WH
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):851-61. PubMed ID: 20107790
[TBL] [Abstract][Full Text] [Related]
20. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.
Kung Sutherland MS; Walter RB; Jeffrey SC; Burke PJ; Yu C; Kostner H; Stone I; Ryan MC; Sussman D; Lyon RP; Zeng W; Harrington KH; Klussman K; Westendorf L; Meyer D; Bernstein ID; Senter PD; Benjamin DR; Drachman JG; McEarchern JA
Blood; 2013 Aug; 122(8):1455-63. PubMed ID: 23770776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
